ZNF215 (zinc finger protein 215) is a transcriptional regulator that functions as a DNA-binding transcription factor involved in RNA polymerase II-mediated transcription. The protein is subject to genomic imprinting in a tissue-specific manner 1. ZNF215 demonstrates clinical significance across multiple cancer types through epigenetic mechanisms. In acute myeloid leukemia, loss of ZNF215 imprinting serves as a predictor of poor five-year survival in patients with cytogenetically abnormal disease 2. Hypermethylation of ZNF215 independently predicts castration-resistant prostate cancer development and disease-specific mortality 3. In gastric adenocarcinoma, ZNF215 expression can be regulated by bacterial microorganisms, with Staphylococcus saccharolyticus promoting gastric cell proliferation through ZNF215 modulation 4. The gene is disrupted in Beckwith-Wiedemann syndrome, where breakpoints affect two of its five alternatively spliced transcripts 1. Additionally, ZNF215 may function as a tumor modifier gene in SDHD-linked paragangliomas, showing decreased protein expression compared to normal tissue 5. These findings establish ZNF215 as an important epigenetic regulator with prognostic value in multiple malignancies.